2017 International Congress

Tuesday, June 6, 2017

1:45pm-3:15pm

Detection of Early Changes in Microbiota Composition in Prodromal Parkinson’s Disease

J. Boertien, T. Van Laar (Groningen, Netherlands)

Parkinson's Disease: Pathophysiology  ·  Exhibit Hall C

1:45pm-3:15pm

Determinant factors of treatment adherence in Parkinson’s disease

I. Estrada-Bellmann, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías, P. Cortés-Estrada (Monterrey, Mexico)

Therapy in Movement Disorders  ·  Exhibit Hall C

1:45pm-3:15pm

Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study

J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

Drug-Induced Movement Disorders  ·  Exhibit Hall C

1:45pm-3:15pm

Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia

J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

Drug-Induced Movement Disorders  ·  Exhibit Hall C

1:45pm-3:15pm

Development of a Paroxysmal Movement Disorder Diary for Patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

R. Hall, S. Kilgariff, P. Collins, M. Brandabur, R. Arbuckle, A. Bowden (Macclesfield, United Kingdom)

Rare Genetic and Metabolic Diseases  ·  Exhibit Hall C

1:45pm-3:15pm

Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy

E. Rockenstein, G. Ostroff, F. Dikengil, F. Rus, M. Mante, J. Florio, A. Adame, I. Trinh, E. Masliah, R. Rissman (La Jolla, CA, USA)

Technology  ·  Exhibit Hall C

1:45pm-3:15pm

Development of nano-formulation containing crocetin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson’s disease model via altered the genetic backgrounds

V. Kumar, A. Verma, P. Bhatt (Allahabad, India)

Parkinson's Disease: Pathophysiology  ·  Exhibit Hall C

1:45pm-3:15pm

Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.

M. Marano, M. Marano, L. di Biase, R. Arca, G. Cossu, E. Coletta, V. Di Lazzaro, A. Fasano, P. Marano (Rome, Italy)

Therapy in Movement Disorders  ·  Exhibit Hall C

1:45pm-3:15pm

Direct dopaminergic responsiveness of activity performance

P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

Therapy in Movement Disorders  ·  Exhibit Hall C

1:45pm-3:15pm

Disappearance of the clinical and imaging manifestations in Wilson’s disease after controlled therapy with tetrathiomolybdate and zinc

I. Posada, C. Garfia, F. Ostos, A. Ramos (Madrid, Spain)

Rare Genetic and Metabolic Diseases  ·  Exhibit Hall C